Advanced Filters
noise

amyloidosis Clinical Trials

A listing of amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 167 clinical trials

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month …

30 years of age All Phase 2
M Mark Chandy, MD PhD

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis. The focus is on its impact on inflammatory and cardiometabolic biomarkers, along with the effects on cardiac function and exercise capacity. Blood samples will be collected at baseline, following each dose …

40 - 80 years of age All Phase 1/2
L Logi El-Harazi

A Study of AMDX-2011P in Participants With CAA

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).

18 years of age All Phase 2
V Veronique Bissay, MD, PhD

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR cardiac amyloidosis (wtTTR-CA). Consequently, explore whether this could ultimately lead to faster diagnosis and clinical outcome of wild-type TTR cardiac amyloidosis (wtTTR-CA).

60 years of age All Phase N/A
S Sharmila Dorbala

Molecular Imaging of Primary Amyloid Cardiomyopathy

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visualize cardiac amyloid deposits using advanced imaging methods. The long-term goal of this work is to identify the mechanisms of cardiac …

18 - 99 years of age All Phase N/A
K Kristine Wilckens, PhD.

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for …

65 - 85 years of age All Phase N/A
S Sarah Bohlman, MSL

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help determine whether diet interventions induce changes in cognitive function, cerebral blood flow, and …

55 - 85 years of age All Phase N/A
J João L. Viana, PhD

Exercise in Hereditary ATTR (ATTRv) Amyloidosis

This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare genetic disease caused by mutations in the transthyretin gene, leading to the deposition of amyloid fibrils in nerves and organs.

18 years of age All Phase N/A
C Christiane Houde

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: screened for the trial via an online platform …

18 years of age All Phase 2
K Kaini Shen

Teclistamab in Previously Treated AL Amyloidosis

This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab

18 years of age All Phase 2

Simplify language using AI